Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURABLE: Alectinib with or without SRS in ALK+ NSCLC with Brain Metastases
NCT05987644Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC), brain metastases. Started Mar 2024; status: recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05987644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987644.